Connect with us

Press Releases

Volition Signs Exclusive $28 Million License and Supply Agreement with Heska Corporation

This is to distribute Nu.Q vet cancer screening test at the point of care.

mm

Published

on

(PRESS RELEASE) AUSTIN, TX — VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, has announced the signing of an exclusive global supply and licensing agreement with Heska Corporation (NASDAQ: HSKA) (“Heska”) to sell its Nu.Q Vet Cancer Screening Test at the point of care for companion animals. Heska is a leading global provider of advanced veterinary diagnostics.

In exchange for granting Heska these exclusive worldwide rights to sell the Nu.Q Vet Cancer Test, Volition will receive:

  • a $10 million upfront payment on signing and
  • up to $18 million based upon the achievement of near/mid-term milestones.

Volition’s licensing agreement with Heska grants exclusive rights to commercialize the Nu.Q Vet Cancer Screening Test for canine cancer screening and monitoring at the point of care. It also enables Heska to access a wider test menu for companion animals, including feline cancer.

In addition, Volition has granted Heska non-exclusive rights to sell the Nu.Q Vet Cancer Screening Test in kit format for companion animals, through Heska’s network of central reference laboratories.

Volition’s Nu.Q Vet Cancer Screening Test will operate on Heska’s proprietary Element i+ Immunodiagnostic Analyzer, a point of care platform. By running the Nu.Q Vet Cancer Screening Test on Heska’s proprietary analyzers and tests, veterinarians will be able to screen millions of pets for some of the most common cancers to provide critical information to pet families accurately, cost effectively, and conveniently at the point of care. Heska’s Nu.Q Vet Cancer Screening Test targets one of the most critical challenges in pet healthcare.

“We are thrilled to announce this agreement with Heska, a company dedicated to developing the next generation of rapid, highly affordable, point-of-care diagnostics for companion animals,” commented Dr. Tom Butera, CEO of Volition Veterinary Diagnostics Development LLC. “We estimate the total addressable market worldwide for cancer screening and monitoring in canines and felines to be approximately $11 billion and growing. As such, we want to make our Nu.Q Vet Cancer Screening Test as accessible as possible to veterinarians around the world, ensure cancer is detected earlier, and improve outcomes for pets and pet owners. Working with Heska, and its global network will enable us to do just that. I am delighted Heska shares our vision of keeping tests very affordable, and we look forward to fostering a successful relationship together and generating ongoing revenue by providing kits and key components to veterinarians around the world.”

Advertisement

“Heska is committed to delivering market-leading technologies to veterinarians through targeted research and development investments and strategic partnerships to get the most urgent innovations into veterinarians’ hands quickly,” commented Kevin Wilson, Heska’s CEO and president. “The accurate, affordable, fast and non-invasive Nu.Q Vet Cancer Screening Test is exactly such an innovation and is a perfect addition to our Heska test menu, which we believe is now the most complete, differentiated and cutting-edge point of care diagnostics solutions stack available for pet healthcare professionals and pet families. With the new Heska Nu.Q Vet Cancer Screening Test millions of pets will have access to critical cancer screening and monitoring instantly, and at the point of care, to catch, treat and drive recovery from cancers earlier and with much better healthcare outcomes and peace of mind.”

Mr. Wilson continued, “Delivering the best care means finding and treating conditions as early as possible in pets who cannot speak for themselves; we must become the voice of the pet to help guide their caregivers. Upon commercialization, which could begin as early as late 2022, we believe our Heska Nu.Q Vet Cancer Screening Test will allow veterinarians across the globe to detect cancer early, in the clinic, in minutes, and for under $50 to support clinical decisions during annual check-ups, regular wellness exams, healthcare interventions, treatment cycles, and remission. Additionally, we see a clear path to developments covering cat cancers and for inclusion of Nu.Q cancer results on multiplexed Heska panels with other key diagnostics relied upon by veterinarians. Leading in cancer will do a great amount of good and I anticipate will accelerate Heska’s 2023 and beyond financial performance even faster than I previously expected.”

The Veterinary Cancer Society estimates one in four dogs and nearly 50% of dogs over the age of 10 will develop cancer. According to the National Cancer Institute, in the U.S. approximately six million new cancer diagnoses are made in dogs each year.

Volition is developing simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including cancer in both humans and animals. For more information about Volition’s Nu.Q technology go to www.volition.com

www.heska.com

Advertisement

Advertisement

FEATURED VIDEO

It’s a Red-Hot Job Market. Here’s What the Industry’s Leading Search Firm Has to Say.

This may be the most challenging job market the pet industry has ever seen. But according to Shaylene Keiner, president of Dolittle Search, it’s still possible to hire the “pick of the litter.” In this Media Spotlight interview, Keiner and interviewer Chloe DiVita talk about all things related to today’s job market, how the “great resignation” has seen many folks reexamining priorities and careers and why working with a search firm can save most companies time and money.

Promoted Headlines

Most Popular